Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic

BACKGROUND: The COVID 19-pandemic has led physicians to change their approach to treating non-small cell lung cancer (NSCLC) to reduce hospital stays for patients. OBJECTIVES: We aimed to assess the toxicity and efficacy of extended interval (EI) dosing of immune checkpoint inhibitors (ICIs) compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Veron, Marie, Pierret, Thomas, Pérol, Maurice, Bettega, François, Benet, Justin, Denis, Natacha, Moro-Sibilot, Denis, Swalduz, Aurélie, Toffart, Anne-Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SPLF and Elsevier Masson SAS. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937999/
https://www.ncbi.nlm.nih.gov/pubmed/37037058
http://dx.doi.org/10.1016/j.resmer.2023.101004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937999/
https://www.ncbi.nlm.nih.gov/pubmed/37037058
http://dx.doi.org/10.1016/j.resmer.2023.101004

Ejemplares similares